Patents by Inventor George Kuo

George Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7790366
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: September 7, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20080318275
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: March 17, 2008
    Publication date: December 25, 2008
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Publication number: 20080191854
    Abstract: A method for actuating a controlled device in response to a pre-crash condition of a vehicle, wherein the vehicle includes at least two sensors each of which is capable of generating a signal, wherein the method includes the steps of monitoring the signals, determining a panic index based upon the signals and, when the determined panic index exceeds a predetermined threshold value, actuating the controlled device.
    Type: Application
    Filed: February 14, 2007
    Publication date: August 14, 2008
    Inventors: Deron C. LittleJohn, Ching C. (George) Kuo, Sanket S. Amberkar
  • Publication number: 20060292556
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Application
    Filed: November 9, 2005
    Publication date: December 28, 2006
    Applicant: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 7138505
    Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage ?FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.
    Type: Grant
    Filed: August 13, 1990
    Date of Patent: November 21, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: George Kuo, Frank Masiarz, Martha Truett, Pablo Valenzuela, Mirella Ezban Rasmussen, Daniel Caput, Rae Lyn Burke, Carol Pachl
  • Patent number: 7105303
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: September 12, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Publication number: 20050202418
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Application
    Filed: December 28, 2004
    Publication date: September 15, 2005
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20050089843
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: October 12, 2004
    Publication date: April 28, 2005
    Inventors: Robert Ralston, Frank Marcus, Kent Thudium, Barbara Gervase, John Hall, Kim Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 6861212
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: March 1, 2005
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20040091851
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 13, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20030232328
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: March 14, 2003
    Publication date: December 18, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20030162167
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: July 25, 1996
    Publication date: August 28, 2003
    Inventors: MICHAEL HOUGHTON, QUI-LIM CHOO, GEORGE KUO
  • Publication number: 20030064499
    Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.
    Type: Application
    Filed: June 18, 2001
    Publication date: April 3, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20030027317
    Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteaces are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.
    Type: Application
    Filed: June 18, 2001
    Publication date: February 6, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 6485113
    Abstract: A haptic braking method and system is disclosed. A controller operates a pump to apply brake fluid to a brake when it is necessary to decelerate a wheel during an active cruise control mode of a vehicle. The controller further operates one or more valves to cyclically vary a pressure level of the brake fluid to cause one or more haptic movements of the brake.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: November 26, 2002
    Assignee: Delphi Technologies, Inc.
    Inventors: Hubert B. Riley, George Kuo
  • Publication number: 20020125769
    Abstract: A haptic braking method and system is disclosed. A controller operates a pump to apply brake fluid to a brake when it is necessary to decelerate a wheel during an active cruise control mode of a vehicle. The controller further operates one or more valves to cyclically vary a pressure level of the brake fluid to cause one or more haptic movements of the brake.
    Type: Application
    Filed: March 8, 2001
    Publication date: September 12, 2002
    Applicant: DELPHI TECHNOLOGIES INC.
    Inventors: Hubert B. Riley, George Kuo
  • Patent number: 6416946
    Abstract: The present invention provides methods and compositions for use therein for typing hepatitis C viruses.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: July 9, 2002
    Assignee: Chiron Corporation
    Inventors: David Y. Chien, George Kuo
  • Patent number: 6416944
    Abstract: The claimed invention provides methods of detecting and typing HCV using nucleic acid molecules encoding type specific and type-cluster specific epitopes. The nucleic acid molecules flanking regions encoding type specific or type cluster specific epitopes are useful in priming the polymerase chain reaction to determine the genotype an HCV isolate.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: July 9, 2002
    Assignee: Chiron Corporation
    Inventors: David Y. Chien, George Kuo
  • Publication number: 20020004048
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: August 13, 2001
    Publication date: January 10, 2002
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 6312889
    Abstract: Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: November 6, 2001
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo